These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 153595)

  • 1. Identification of high molecular weight derivatives of plasmic digests of cross-linked human fibrin.
    Regañon E; Vila V; Aznar J
    Thromb Haemost; 1978 Oct; 40(2):368-76. PubMed ID: 153595
    [No Abstract]   [Full Text] [Related]  

  • 2. Fibrin and fibrinogen proteolysis products: comparison between gel filtration and SDS polyacrylamide electrophoresis analysis.
    Alkjaersig N; Davies A; Fletcher A
    Thromb Haemost; 1977 Aug; 38(2):524-5. PubMed ID: 145666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of soluble cross-linked fibrin in D dimer immunoreactivity of plasmic digests.
    Brenner B; Francis CW; Marder VJ
    J Lab Clin Med; 1989 Jun; 113(6):682-8. PubMed ID: 2732616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenic markers on fragment DD, a unique plasmic derivative of human crosslinked fibrin.
    Budzynski AZ; Marder VJ; Parker ME; Shames P; Brizuela BS; Olexa SA
    Blood; 1979 Oct; 54(4):794-804. PubMed ID: 157788
    [No Abstract]   [Full Text] [Related]  

  • 5. Lymphocyte suppressive peptides from fibrinogen are derived predominantly from the A alpha chain.
    Plow EF; Edgington TS
    J Immunol; 1986 Sep; 137(6):1910-5. PubMed ID: 2943807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmic degradation of fibrinogen Paris I.
    Budzynski AZ; Marder VJ
    J Lab Clin Med; 1976 Nov; 88(5):817-25. PubMed ID: 978044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular composition and biological properties of soluble fibrin polymers encountered in thrombotic states.
    Bang NU; Hansen MS; Smith GF; Latallo ZS; Chang ML; Mattler LE
    Ser Haematol; 1973; 6(4):494-512. PubMed ID: 4277578
    [No Abstract]   [Full Text] [Related]  

  • 8. [Immuno-nephelometric characterization of fibrinogen derivatives and of fibrin after chromatography].
    Haarsma M; Mensi N; Roth M; Bouvier CA
    Schweiz Med Wochenschr; 1974 Sep; 104(39):1368-9. PubMed ID: 4279067
    [No Abstract]   [Full Text] [Related]  

  • 9. Degradation of cross-linked fibrin by human leukocyte proteases.
    Francis CW; Marder VJ
    J Lab Clin Med; 1986 Apr; 107(4):342-52. PubMed ID: 3514776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Degradation of non cross-linked and cross-linked fibrin clots by plasmin, trypsin, chymotrypsin and Brinase.
    Gormsen J; Feddersen C
    Thromb Res; 1974 Aug; 5(2):125-39. PubMed ID: 4278050
    [No Abstract]   [Full Text] [Related]  

  • 11. [Identification and preparation of high-molecular derivatives of fibrinogen from human plasma by means of PAA-gel electrophoresis and agarose-gel chromatography].
    von Hugo R; Graeff H
    Thromb Diath Haemorrh Suppl; 1973; 55():325-37. PubMed ID: 4216114
    [No Abstract]   [Full Text] [Related]  

  • 12. The detection of neoantigenic sites on the D-dimer peptide isolated from plasmin digested cross linked fibrin.
    Lee-Own V; Gordon YB; Chard T
    Thromb Res; 1979 Jan; 14(1):77-84. PubMed ID: 154752
    [No Abstract]   [Full Text] [Related]  

  • 13. Fibrin-I degradation products with a molecular weight higher than that of fibrinogen. Identification and characterization of in vitro products from human plasma.
    von Hugo R; Graeff H
    Thromb Diath Haemorrh; 1973 Feb; 29(1):122-9. PubMed ID: 4708590
    [No Abstract]   [Full Text] [Related]  

  • 14. [Analysis of cross-linked fibrin and fibrinogen degradation products with SDS-PAGE and immunoblot].
    Okumura N; Kagiya H; Kumagai T; Kameko M; Tozuka M; Saito H; Katsuyama T; Kanai M
    Rinsho Byori; 1990 Feb; 38(2):201-7. PubMed ID: 2329722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstration of different D-and E-antigenic intermediates during plasmin degradation of non-stabilized and stabilized fibrin clots.
    Gormsen J; Feddersen C
    Scand J Haematol; 1973; 10(5):337-48. PubMed ID: 4272382
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of fibrinogen derivatives in plasma samples.
    Graeff H; von Hugo R
    Thromb Diath Haemorrh; 1972 Jul; 27(3):610-8. PubMed ID: 4197047
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasmic degradation of crosslinked fibrin. I. Structural analysis of the particulate clot and identification of new macromolecular-soluble complexes.
    Francis CW; Marder VJ; Martin SE
    Blood; 1980 Sep; 56(3):456-64. PubMed ID: 6447526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and purification of fibrinogen degradation products produced by plasmin: considerations on the structure of fibrinogen.
    Marder VJ
    Scand J Haematol Suppl; 1971; 13():21-36. PubMed ID: 4258202
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure.
    Francis CW; Marder VJ; Barlow GH
    J Clin Invest; 1980 Nov; 66(5):1033-43. PubMed ID: 6448866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of DL and DH degradation products in the reactions of the plasmin hydrolysis of fibrinogen and fibrin].
    Rozenfel'd MA; Leonova VB; Khavkina LS
    Izv Akad Nauk SSSR Biol; 1991; (3):334-42. PubMed ID: 1835465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.